Spectral AI, Inc. — Form 8-K
Filed September 15, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
On May 21, 2026, Spectral AI obtained FDA De Novo classification for its DeepView burn-wound healing prediction system, authorizing U.S. commercial sales. The company has secured a $150M BARDA contract with $86.6M committed to date, supporting deployment of 30 subsidized systems to U.S. burn/trauma centers. First commercial sales are targeted by year-end 2026. At June 30, 2026, the company held $14.0M cash against $14.9M notes payable and a $12.1M stockholders' deficit; H1 2026 revenue was $7.5M (down from $19.7M in FY2025 due to completion of development programs).
Why this rating
FDA De Novo clearance removes the largest regulatory hurdle and validates 13-year, $250M+ development effort. $86.6M committed BARDA funding and pathway to recurring revenue represent material near-term revenue potential relative to $72M market cap. However, company is unprofitable, burning cash, and commercial execution risk remains high.
Price action (we called it positive)
before filing · preread $0.49 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.